Landes Bioscience has announced the start of a new peer-reviewed journal, Biopharmaceuticals, with its first issue to be published in early 2011. Biopharmaceuticals will be the first peer-reviewed periodical solely concerned with biopharmaceuticals, the most complex of all commercial products. Individual online subscriptions will be free during the first year.
Biopharmaceuticals are pharmaceuticals manufactured by or using living organisms. Biopharmaceuticals are rapidly increasing in number and importance, with over 600 currently marketed in the U.S. and European markets alone, a large number in development, and their number and percentage steadily increasing relative to small-molecule drugs. The discovery, development, manufacture and marketing of biopharmaceuticals require an integrated understanding of their scientific, technological and commercial/societal aspects. Only those most knowledgeable concerning the diverse aspects of these products will be successful. The situation is getting even more complex as large numbers of biosimilars and biogenerics enter markets worldwide.
Mr. Ronald A. Rader, editor-in-chief, notes, "Biopharmaceuticals is designed to serve the information needs of those involved with biopharmaceutical research, development, regulation, technology transfer and marketing. Articles will go beyond reporting laboratory findings and include discussions of the relevance of new scientific findings, technologies, regulations, patents, products and marketing trends. This includes reviews, reports, commentaries and case studies in diverse areas, including the nature and characterization of biopharmaceuticals, agent discovery and design, issues in product development, financing, clinical testing, regulatory approvals, patents and licensing, manufacturing, technology and market assessments and projections, scientific controversies and politics."
Articles are now being accepted for review and publication. There are no page or other publication charges during the first year. Volunteers are also needed to serve on the Editorial Board and host topical sections. For further information, contact:
Ronald A. Rader
Editor-in-Chief, Biopharmaceuticals
Landes Bioscience
Phone: 301-424-0255
E-mail: rader@landesbioscience.com
Journal website: www.landesbioscience.com/journals/biopharma/
Source: Landes Bioscience
Many relevant diagnostic signs are not performed deliberately by the examiner or by the patient at the examiner’s direction. They are observed as the patient reacts to their condition. Fortin’s finger sign, Minor’s sign, and Vanzetti’s sign are three examples of this principle.
Spearheaded by burgeoning scientific and clinical research literature, psychedelics have reached a level of media coverage and popular interest that has not been seen for over half a century. By “psychedelics,” we are referring to the unique class of substances that includes psilocybin (the active compound found in so-called “magic mushrooms”), LSD, dimethyltryptamine (DMT), ayahuasca, 5-MeO-DMT, and mescaline – each of which occurs in the natural world (except for LSD, which is a semi-synthetic compound).
While working at the Lovelace Medical Center in Albuquerque, N.M., one of the primary care physicians stated that imaging every patient prior to receiving chiropractic was not medically necessary. It was at that point I reconsidered the need for the imaging of every patient to avoid malpractice.
